Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 19/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19726801 | 0.79 | BRD4 (0.45) | BRD4BRD2CREBBP | |
| SCHEMBL20577934 | 0.79 | ERN1 (0.54) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL19726804 | 0.77 | ERN1 (0.52) | ERN1BRD4 | |
| SCHEMBL20689265 | 0.76 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL19231554 | 0.74 | ERN1 (0.49) | ERN1BRD4 | |
| SCHEMBL19231446 | 0.74 | BRD4 (0.55) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL19231421 | 0.73 | ERN1 (0.48) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL19231555 | 0.73 | ERN1 (0.47) | ERN1BRD4CREBBP | |
| SCHEMBL1664331 | 0.72 | ERN1 (0.59) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL17813564 | 0.72 | BRD4 (0.66) | ERN1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360765-A1 | SUBSTITUTED PYRIDINES AS BROMODOMAiN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360765-A1 | SUBSTITUTED PYRIDINES AS BROMODOMAiN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360765-A1 | SUBSTITUTED PYRIDINES AS BROMODOMAiN INHIBITORS | BRD4, BRDT, BRD3 | ERN1 1762/4885BRD4 1/4885BRD2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.